Golden State Equity Partners Invests $1.12 Million in Amgen Inc. (NASDAQ:AMGN)

Golden State Equity Partners acquired a new stake in shares of Amgen Inc. (NASDAQ:AMGNFree Report) in the first quarter, HoldingsChannel reports. The fund acquired 4,619 shares of the medical research company’s stock, valued at approximately $1,117,000.

A number of other large investors have also recently bought and sold shares of AMGN. Tanglewood Legacy Advisors LLC bought a new stake in shares of Amgen in the 4th quarter worth approximately $26,000. Ruedi Wealth Management Inc. acquired a new stake in Amgen in the fourth quarter worth $27,000. Strategic Investment Solutions Inc. IL bought a new stake in Amgen in the first quarter valued at $28,000. GW&K Investment Management LLC boosted its holdings in shares of Amgen by 200.0% during the fourth quarter. GW&K Investment Management LLC now owns 120 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 80 shares during the period. Finally, AXS Investments LLC bought a new position in shares of Amgen during the fourth quarter worth about $33,000. Institutional investors own 74.44% of the company’s stock.

Amgen Stock Performance

Shares of NASDAQ AMGN opened at $257.23 on Thursday. The stock’s fifty day simple moving average is $245.86 and its 200 day simple moving average is $237.17. The stock has a market capitalization of $137.59 billion, a price-to-earnings ratio of 17.35, a PEG ratio of 3.20 and a beta of 0.61. The company has a quick ratio of 2.48, a current ratio of 2.77 and a debt-to-equity ratio of 8.76. Amgen Inc. has a 52-week low of $211.71 and a 52-week high of $296.67.

Amgen (NASDAQ:AMGNGet Free Report) last released its quarterly earnings results on Thursday, August 3rd. The medical research company reported $5.00 earnings per share for the quarter, beating analysts’ consensus estimates of $4.44 by $0.56. The business had revenue of $7 billion during the quarter, compared to analyst estimates of $6.66 billion. Amgen had a return on equity of 196.60% and a net margin of 30.02%. Amgen’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the company posted $4.65 EPS. As a group, sell-side analysts forecast that Amgen Inc. will post 18.35 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Friday, August 18th were paid a dividend of $2.13 per share. This represents a $8.52 dividend on an annualized basis and a dividend yield of 3.31%. The ex-dividend date of this dividend was Thursday, August 17th. Amgen’s dividend payout ratio (DPR) is presently 57.45%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Argus cut their price target on Amgen from $270.00 to $260.00 in a report on Monday, June 26th. Barclays cut their price objective on shares of Amgen from $225.00 to $210.00 in a research note on Tuesday, July 11th. Credit Suisse Group lowered their target price on shares of Amgen from $220.00 to $200.00 in a research note on Wednesday, July 12th. Mizuho upped their price target on shares of Amgen from $214.00 to $223.00 and gave the stock a “neutral” rating in a research note on Monday, August 14th. Finally, Oppenheimer reiterated an “outperform” rating and set a $280.00 price objective on shares of Amgen in a research note on Tuesday, July 25th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $264.19.

Check Out Our Latest Stock Analysis on AMGN

Insider Activity at Amgen

In other Amgen news, EVP Murdo Gordon sold 9,558 shares of Amgen stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $262.43, for a total value of $2,508,305.94. Following the completion of the sale, the executive vice president now directly owns 44,308 shares in the company, valued at $11,627,748.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.46% of the stock is currently owned by company insiders.

About Amgen

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh├žet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Featured Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.